title: [A prospective study on the effects of levonorgestrel-releasing intrauterine system for adenomyosis with menorrhagia].
abstract: OBJECTIVE
  To investigate treatment effects of levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis with menorrhea in a prospective study.
  
  
  METHODS
  From December 2006 to December 2014, patients of symptomatic adenomyosis diagnosed by transvaginal ultrasound in outpatient or inpatient clinics of Peking Union Medical College Hospital were given the treatment of LNG-IUS. Before and after placement of LNG-IUS, all the patients' parameters were recorded prospectively, including scores of menstruation blood loss, carrying status of IUS, symptoms and scores of dysmenorrhea, biochemical indicators, physical parameters, menstruation patterns and adverse effects. Changes of pictorial chart scores of menstruation and distribution of anemia during follow-up were analyzed.
  
  
  RESULTS
  Totally 1 100 women meets inclusion criteria, among which 618 cases (56.18%, 618/1 100) had severe menorrhea, with median follow-up period of 28 months (range 1- 60 months), and accumulative carrying rate of 66% at 60 months follow-up. After placement of LNG-IUS, compared with baselines, pictorial chart scores and ratio of menorrhea had decreased significantly (all P<0.01), the scroes of menstruation were 157±34, 94±35, 70±33, 67±18, 67±20, 65±19, 66±19, 65±21 at 0, 3, 6, 12, 24, 36, 48 and 60 months respectively. During 24 months after placement of LNG-IUS, pictorial chart scores and distribution of anemia had improved significantly compared with preceding period (all P<0.01). We found no dependent factors predicting improvement of pictorial chart scores of menorrhea, which was neither relevant with simultaneous changes of menstruation patterns nor adverse effects (all P>0.05).
  
  
  CONCLUSIONS
  LNG-IUS is effective for adenomyosis of menorrhea. Improvement of menstruation blood loss is independent on patients characters, menstruation patterns or adverse effects.
authors.affiliation: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: J H
authors.initials: JH
authors.lastname: Leng
authors.forename: J H
authors.initials: JH
authors.lastname: Shi
authors.forename: J J
authors.initials: JJ
authors.lastname: Zhang
authors.forename: S Z
authors.initials: SZ
authors.lastname: Jia
authors.forename: X Y
authors.initials: XY
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Dai
authors.forename: J R
authors.initials: JR
authors.lastname: Zhang
authors.forename: T
authors.initials: T
authors.lastname: Li
authors.forename: X X
authors.initials: XX
authors.lastname: Xu
authors.forename: Z Z
authors.initials: ZZ
authors.lastname: Liu
authors.forename: S S
authors.initials: SS
authors.lastname: You
authors.forename: X Y
authors.initials: XY
authors.lastname: Chang
authors.forename: J H
authors.initials: JH
authors.lastname: Lang
mesh_terms: D062788:Adenomyosis / Q000188:drug therapy*; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D004412:Dysmenorrhea / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D008595:Menorrhagia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008598:Menstruation; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D003271:Contraceptive Agents, Female; D016912:Levonorgestrel